A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States
Background: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives. Methods: A Susceptible–Exposed–Infectious–Recovered (SEIR) tra...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/11/1217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850227893338112000 |
|---|---|
| author | Myron J. Levin Neda Al Rawashdh Liliane Mofor Pablo Anaya Richard M. Zur Emily B. Kahn Daniel Yu Joaquin F. Mould-Quevedo |
| author_facet | Myron J. Levin Neda Al Rawashdh Liliane Mofor Pablo Anaya Richard M. Zur Emily B. Kahn Daniel Yu Joaquin F. Mould-Quevedo |
| author_sort | Myron J. Levin |
| collection | DOAJ |
| description | Background: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives. Methods: A Susceptible–Exposed–Infectious–Recovered (SEIR) transmission model of the total US population followed with a cost-effectiveness model for 18–64-year-olds was used to estimate the clinical and economic impact of vaccination over one influenza season (2018–2019). Deterministic and probabilistic sensitivity analyses were conducted. Results: Both enhanced vaccines prevented a substantial number of influenza cases and influenza-related deaths compared to no vaccination. The cell-based vaccine was associated with higher quality-adjusted life years (QALYs) gained compared to the recombinant vaccine or no vaccination. The cell-based vaccine had a 36% lower vaccination cost, amounting to $2.8 billion in cost savings, compared to the recombinant vaccine. The incremental cost-effectiveness ratios (ICERs) for the cell-based vaccine, compared to the recombinant vaccine or no vaccination, were dominant from all payer perspectives, regardless of risk groups. Conclusions: Overall, the cell-based vaccine was cost-saving compared to the recombinant vaccine for subjects aged 18–64 years in the US, achieving comparable health outcomes with a significant reduction in associated costs. |
| format | Article |
| id | doaj-art-a85705b5e64a49e1b16857bd5d17a1ce |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-a85705b5e64a49e1b16857bd5d17a1ce2025-08-20T02:04:41ZengMDPI AGVaccines2076-393X2024-10-011211121710.3390/vaccines12111217A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United StatesMyron J. Levin0Neda Al Rawashdh1Liliane Mofor2Pablo Anaya3Richard M. Zur4Emily B. Kahn5Daniel Yu6Joaquin F. Mould-Quevedo7Departments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USAReal-World Solutions, IQVIA, Falls Church, VA 22042, USACSL Seqirus USA, Summit, NJ 07901, USAReal-World Solutions, IQVIA, Falls Church, VA 22042, USAReal-World Solutions, IQVIA, Falls Church, VA 22042, USAReal-World Solutions, IQVIA, Falls Church, VA 22042, USACSL Seqirus Australia, Melbourne 3052, AustraliaCSL Seqirus USA, Summit, NJ 07901, USABackground: This analysis compares the cost-effectiveness of a cell-based influenza vaccine to a recombinant influenza vaccine, and each to no vaccination. The analysis is based on United States (US) commercial and societal perspectives. Methods: A Susceptible–Exposed–Infectious–Recovered (SEIR) transmission model of the total US population followed with a cost-effectiveness model for 18–64-year-olds was used to estimate the clinical and economic impact of vaccination over one influenza season (2018–2019). Deterministic and probabilistic sensitivity analyses were conducted. Results: Both enhanced vaccines prevented a substantial number of influenza cases and influenza-related deaths compared to no vaccination. The cell-based vaccine was associated with higher quality-adjusted life years (QALYs) gained compared to the recombinant vaccine or no vaccination. The cell-based vaccine had a 36% lower vaccination cost, amounting to $2.8 billion in cost savings, compared to the recombinant vaccine. The incremental cost-effectiveness ratios (ICERs) for the cell-based vaccine, compared to the recombinant vaccine or no vaccination, were dominant from all payer perspectives, regardless of risk groups. Conclusions: Overall, the cell-based vaccine was cost-saving compared to the recombinant vaccine for subjects aged 18–64 years in the US, achieving comparable health outcomes with a significant reduction in associated costs.https://www.mdpi.com/2076-393X/12/11/1217cell-based influenza vaccinerecombinant influenza vaccinecost-effectivenessUnited States |
| spellingShingle | Myron J. Levin Neda Al Rawashdh Liliane Mofor Pablo Anaya Richard M. Zur Emily B. Kahn Daniel Yu Joaquin F. Mould-Quevedo A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States Vaccines cell-based influenza vaccine recombinant influenza vaccine cost-effectiveness United States |
| title | A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States |
| title_full | A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States |
| title_fullStr | A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States |
| title_full_unstemmed | A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States |
| title_short | A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States |
| title_sort | clinical and economic comparison of cell based versus recombinant influenza vaccines in adults 18 64 years in the united states |
| topic | cell-based influenza vaccine recombinant influenza vaccine cost-effectiveness United States |
| url | https://www.mdpi.com/2076-393X/12/11/1217 |
| work_keys_str_mv | AT myronjlevin aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT nedaalrawashdh aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT lilianemofor aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT pabloanaya aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT richardmzur aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT emilybkahn aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT danielyu aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT joaquinfmouldquevedo aclinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT myronjlevin clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT nedaalrawashdh clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT lilianemofor clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT pabloanaya clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT richardmzur clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT emilybkahn clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT danielyu clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates AT joaquinfmouldquevedo clinicalandeconomiccomparisonofcellbasedversusrecombinantinfluenzavaccinesinadults1864yearsintheunitedstates |